ELITE PHARMACEUTICALS, INC /NV/ — Income Charts
2 years of history · ending 2025-03-31 · SEC EDGAR
Source:10-K · 10-Q
Revenue, Gross Profit, Operating Income & Net Income
Margin (%)
Operating Expenses
Income Breakdown
Revenue
$84M
Cost of Revenue
$44M
Gross Profit
$40M
R&D
$8M
D&A
$1M
Operating Income
$20M
EBITDA
$21M
Interest Expense
$128K
Interest Income
$21K
Other Income/Expense
$-20M
Pretax Income
$-52K
Tax Provision
$4M
Net Income
$-4M
Gross Margin
47.7%
Operating Margin
23.3%
Net Margin
-5.1%
Effective Tax Rate
-8175.1%
Deferred Tax Assets
$18M
Deferred Tax Liabilities
$22M
DTA Valuation Allowance
—
NOL Carryforwards
$51M
Operating Lease Cost
—
Revenue YoY Variation
48.4%
Income YoY Variation
81.7%